APA (7th ed.) Citation

Alexandre, M., Bohelay, G., Gille, T., Le Roux-Villet, C., Soued, I., Morin, F., . . . Prost-Squarcioni, C. (2022). Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients. Frontiers in immunology, 13, 874108. https://doi.org/10.3389/fimmu.2022.874108

Chicago Style (17th ed.) Citation

Alexandre, Marina, Gérôme Bohelay, Thomas Gille, Christelle Le Roux-Villet, Isaac Soued, Florence Morin, Frédéric Caux, Sabine Grootenboer-Mignot, and Catherine Prost-Squarcioni. "Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients." Frontiers in Immunology 13 (2022): 874108. https://doi.org/10.3389/fimmu.2022.874108.

MLA (9th ed.) Citation

Alexandre, Marina, et al. "Rapid Disease Control in First-Line Therapy-Resistant Mucous Membrane Pemphigoid and Bullous Pemphigoid with Omalizumab as Add-On Therapy: A Case Series Of 13 Patients." Frontiers in Immunology, vol. 13, 2022, p. 874108, https://doi.org/10.3389/fimmu.2022.874108.